US FDA inspection of Satara facility ends with 1 procedural observation

Regulatory & Legal View source PDF Explain this filing

RUBICON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹1550.10

prior close

₹1557.60

announcement price

After-mkt

timing

Nifty Smallcap 250market+1.1%-1.3% vs market

Pharmaceuticals peers, median of 167sector-0.1%-0.1% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.8

15m

-0.2

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+1.1-1.3-0.1-0.1

Next day

-1.7+1.5-3.1-0.1-1.5

-1.5+1.5-2.9-0.2-1.2

-4.2+0.3-4.5-0.9-3.3

-2.7+0.4-3.0-0.7-1.9

-4.4-0.8-3.6-2.2-2.2

-8.3-4.1-4.2-4.4-3.9

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The US FDA conducted an unannounced inspection of Rubicon Research's Satara, Maharashtra manufacturing facility from October 5 to October 9, 2026. A Form 483 was issued with one procedural observation that does not relate to data integrity. The company is confident of resolving it. If closed successfully, this would be the first successful unannounced inspection for the Satara site, and Rubicon's third such inspection in FY2026-27.

Likely market impact

Positive: only 1 procedural observation, no data integrity issues. Third unannounced FDA inspection success in FY27 if closed, boosting credibility.